Create Free Account

By creating account you will get access to hot stocks & personalised emails

Firebrick Pharma Ltd

Healthcare AU FRE

0.052AUD
-0.002(3.70%)

Last update at 2024-11-12T23:49:00Z

Day Range

0.050.05
LowHigh

52 Week Range

0.040.11
LowHigh

Fundamentals

  • Previous Close 0.05
  • Market Cap11.98M
  • Volume13771
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.08469M
  • Revenue TTM2.75M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.02M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.80207M -3.79631M -2.43904M -1.49848M -0.72526M
Minority interest - - - - -
Net income -6.80207M -3.79631M -2.43904M -1.49848M -0.72526M
Selling general administrative 2.76M 0.50M 1.73M 0.38M 0.12M
Selling and marketing expenses - 0.33M - - -
Gross profit 0.00083M 0.00412M - - -
Reconciled depreciation 0.00952M 0.00694M - - -
Ebit -6.75187M -3.79217M -2.43980M -1.49900M -
Ebitda -6.85422M -3.78523M - - -
Depreciation and amortization - 0.00694M - - -
Non operating income net other - - - - -
Operating income -6.86374M -3.79217M -2.86180M -2.00798M -1.17337M
Other operating expenses 0.19M 4.88M 0.07M 0.07M -
Interest expense - 0.00414M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.04M 0.00128M 0.00076M 0.00052M 0.00314M
Net interest income 0.04M -0.00286M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 1.08M - - -
Total revenue 0.00083M 0.00412M 0.00000M 0.00000M 0.00000M
Total operating expenses - 4.88M - - -
Cost of revenue - - - - -
Total other income expense net 0.02M 1.08M - - -
Discontinued operations - - - - -
Net income from continuing ops -6.80207M -3.79631M - - -
Net income applicable to common shares -6.80207M -3.79631M -2.43904M -1.49848M -0.72526M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 2.41M 2.98M 8.73M 11.77M 0.65M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.08M 0.10M 0.00535M 0.01M -
Total liab 0.29M 0.51M 0.45M 0.21M 0.26M
Total stockholder equity 2.12M 2.48M 8.28M 11.55M 0.39M
Deferred long term liab - - - - -
Other current liab 0.22M 0.17M 0.41M 0.08M -
Common stock 17.88M 17.07M 16.00M 15.99M 2.66M
Capital stock - 17.07M 16.00M 15.99M -
Retained earnings -16.51202M -15.57866M -8.80510M -5.23911M -2.59475M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 0.36M 0.36M 0.08M -
Cash 0.82M 2.35M 7.14M 10.88M 0.09M
Cash and equivalents - - - - -
Total current liabilities 0.29M 0.51M 0.45M 0.21M 0.21M
Current deferred revenue - - - - -
Net debt -0.82478M - -7.14290M -10.87588M -
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - 0.99M 1.08M 0.81M 0.33M
Property plant equipment - 0.03M 0.04M 0.02M 0.00060M
Total current assets 2.09M 2.59M 8.33M 11.68M 0.65M
Long term investments - - - - -
Net tangible assets - 2.48M 8.28M 1.55M 0.39M
Short term investments - - - 0.28M -
Net receivables 0.95M 0.14M 1.08M 0.50M 0.56M
Long term debt - - - - -
Inventory 0.24M - 0.10M - -
Accounts payable 0.07M 0.20M 0.04M 0.14M 0.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.74M - 1.08M 0.81M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.29M 0.36M 0.36M 0.08M -
Deferred long term asset charges - - - - -
Non current assets total 0.31M 0.39M 0.40M 0.09M -
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.00162M -0.03254M - - -
Change to liabilities 0.06M 0.20M -0.07110M 0.17M -
Total cashflows from investing activities -0.00162M -0.03254M -0.01607M -0.01607M -
Net borrowings - - - - -
Total cash from financing activities 1.00M 10.23M 3.01M 0.50M 1.26M
Change to operating activities 0.00711M -0.05015M -0.01275M 0.09M -
Net income -6.80207M -3.79631M -2.43904M -1.49848M -
Change in cash -4.78832M 5.99M 1.06M -0.48476M 0.19M
Begin period cash flow 7.14M 1.15M - - -
End period cash flow 2.35M 7.14M 1.15M - -
Total cash from operating activities -5.78336M -4.20223M -1.93610M -0.98501M -1.06447M
Issuance of capital stock 1.00M 10.70M - - -
Depreciation 0.00952M 0.00694M 0.00052M 0.00030M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - -0.28324M -0.28324M -0.28324M -
Change to account receivables 0.94M -0.57849M 0.05M -0.05223M -
Sale purchase of stock 1.00M -0.47408M 3.13M 0.41M 0.69M
Other cashflows from financing activities -0.00626M 0.11M -0.11637M -0.11637M 0.57M
Change to netincome 0.00211M 0.30M 0.53M 0.30M -
Capital expenditures 0.00162M 0.03M 0.02M 0.02M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.25429M -2.80772M -1.53630M -0.98501M -1.09742M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -5.78497M -0.03254M - - -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRE
Firebrick Pharma Ltd		 -0.002 3.70% 0.05 - - 4.35 5.56 753.43 -8.0904
MYX
Mayne Pharma Group Ltd		 -0.41 7.74% 4.89 - 285.71 0.97 0.83 0.68 -1.0926

Reports Covered

Stock Research & News

View All

Profile

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.

Firebrick Pharma Ltd

440 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Exec. Chairman & CEO 1954
Dr. Stephen Francis Goodall MASc, MBA Founder, COO & Exec. Director NA
Mr. Kavi Bekarma B.Sc., C.A. Chief Financial Officer NA
Dr. Simon Tucker Chief Scientific Officer NA
Ms. Robyn Branigan Head of Marketing NA
Prof. Peter Friedland Chief Medical Officer NA
Dr. Monique Baldwin Head of Regulatory Affairs NA
Ms. Kyla Garic Exec. Officer NA
Mr. Stephen Buckley Company Sec. NA
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Executive Chairman & CEO 1954

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.